Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-Year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial

Claus Roehrborn, Jack Barkin, Paul Siami, Andrea Tubaro, Timothy H. Wilson, Betsy B. Morrill, R. Paul Gagnier

Urology
Urology - Adult

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-Year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial'. Together they form a unique fingerprint.

Sort by
Weight
Alphabetically

Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-Year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial

Fingerprint

Medicine & Life Sciences